Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Products under Development by Stage of Development | 8 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Products under Development by Therapy Area | 9 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Products under Development by Indication | 10 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Products under Development by Companies | 12 | 2 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Therapeutics Assessment | 14 | 7 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 2 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Companies Involved in Therapeutics Development | 21 | 9 |
| Alligator Bioscience AB | 21 | 1 |
| Apogenix GmbH | 22 | 1 |
| BioInvent International AB | 23 | 1 |
| Bristol-Myers Squibb Company | 24 | 1 |
| Enumeral Biomedical Holdings, Inc. | 25 | 1 |
| Genentech, Inc. | 26 | 1 |
| GlaxoSmithKline Plc | 27 | 1 |
| MedImmune, LLC | 28 | 1 |
| Pfizer Inc. | 29 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Drug Profiles | 30 | 14 |
| ADC-1015 Drug Profile | 30 | 1 |
| BMS-986178 Drug Profile | 31 | 1 |
| Delta-24-RGDOX Drug Profile | 32 | 1 |
| durvalumab + MEDI-6383 Drug Profile | 33 | 1 |
| GSK-3174998 Drug Profile | 34 | 1 |
| MEDI-0562 Drug Profile | 35 | 2 |
| MEDI-6383 Drug Profile | 37 | 1 |
| Monoclonal Antibodies to Agonize OX40 for Oncology Drug Profile | 38 | 1 |
| Monoclonal Antibodies to Agonize OX40 for Oncology Drug Profile | 39 | 1 |
| PF-04518600 Drug Profile | 40 | 1 |
| Recombinant Protein to Agonize OX40 for Solid Tumor Drug Profile | 41 | 1 |
| Recombinant Proteins to Agonize OX40 and Notch 3 for Type 1 Diabetes Drug Profile | 42 | 1 |
| RG-7888 Drug Profile | 43 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Dormant Projects | 44 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Discontinued Products | 45 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Featured News &Press Releases | 46 | 3 |
| Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment | 46 | 1 |
| Oct 20, 2014: AgonOx s OX40 Platform Being Utilized in MedImmune s Phase 1 OX40 Agonist Study | 46 | 1 |
| Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy | 47 | 2 |
| Appendix | 49 | 2 |
| Methodology | 49 | 1 |
| Coverage | 49 | 1 |
| Secondary Research | 49 | 1 |
| Primary Research | 49 | 1 |
| Expert Panel Validation | 49 | 1 |
| Contact Us | 49 | 1 |
| Disclaimer | 50 | 1 |